Xenetic Biosciences Files 8-K Report
Ticker: XBIO · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1534525
| Field | Detail |
|---|---|
| Company | Xenetic Biosciences, Inc. (XBIO) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Xenetic Biosciences filed an 8-K, standard disclosure, check for material updates.
AI Summary
On December 11, 2025, Xenetic Biosciences, Inc. filed an 8-K report. The filing primarily serves as a notification of events and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Xenetic Biosciences is making a regulatory disclosure, which could precede or follow significant corporate actions or financial updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without immediate disclosure of significant negative events.
Key Players & Entities
- Xenetic Biosciences, Inc. (company) — Registrant
- December 11, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-37937 (identifier) — Commission File Number
- 45-2952962 (identifier) — IRS Employer Identification No.
- 945 Concord Street, Framingham, Massachusetts 01701 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Xenetic Biosciences, Inc.?
The 8-K filing serves as a Current Report to notify the SEC of events that shareholders should be aware of, and it includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated December 11, 2025.
In which state is Xenetic Biosciences, Inc. incorporated?
Xenetic Biosciences, Inc. is incorporated in Nevada.
What is the Commission File Number for Xenetic Biosciences, Inc.?
The Commission File Number for Xenetic Biosciences, Inc. is 001-37937.
What are the principal executive offices of Xenetic Biosciences, Inc.?
The principal executive offices are located at 945 Concord Street, Framingham, Massachusetts 01701.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-12-11 17:00:43
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq
Filing Documents
- xenetic_8k.htm (8-K) — 27KB
- xenetic_ex9901.htm (EX-99.1) — 15KB
- image_001.jpg (GRAPHIC) — 6KB
- 0001683168-25-009076.txt ( ) — 216KB
- xbio-20251211.xsd (EX-101.SCH) — 3KB
- xbio-20251211_lab.xml (EX-101.LAB) — 33KB
- xbio-20251211_pre.xml (EX-101.PRE) — 22KB
- xenetic_8k_htm.xml (XML) — 3KB
01
Item 7.01. Regulation FD Disclosure. On December 11, 2025, Xenetic Biosciences, Inc. (the "Company") issued a press release announcing that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") that convened on December 11, 2025 has been adjourned until January 8, 2026 at 10:00 a.m. Eastern Time in order to achieve a quorum and allow additional time to solicit additional proxies on behalf of the Company's board of directors. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENETIC BIOSCIENCES, INC. By: /s/ James Parslow Date: December 11, 2025 Name: James Parslow Title: Interim Chief Executive Officer and Chief Financial Officer 3